Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RabOCT: Lucentis Re-treatment Guided by OCT in BRVO
NCT01968239Phase 2Completed
- Sponsor
- Leipzig University
- Start
- Oct 2013
- Primary completion
- Jun 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in branch retinal vein occlusion (BRVO), sponsored by Leipzig University. Started Oct 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT01968239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01968239.